Danaher (NYSE:DHR) Price Target Cut to $260.00 by Analysts at Evercore ISI

Danaher (NYSE:DHR) had its price objective lowered by research analysts at Evercore ISI from $266.00 to $260.00 in a note issued to investors on Tuesday, Benzinga reports. The brokerage presently has an “outperform” rating on the conglomerate’s stock. Evercore ISI’s price target indicates a potential upside of 7.94% from the stock’s current price.

Several other research firms have also weighed in on DHR. Jefferies Financial Group initiated coverage on Danaher in a research note on Monday, June 3rd. They issued a “buy” rating and a $295.00 price objective on the stock. Barclays lifted their price target on shares of Danaher from $260.00 to $270.00 and gave the company an “equal weight” rating in a report on Wednesday, April 24th. TD Cowen raised their price objective on shares of Danaher from $280.00 to $290.00 and gave the stock a “buy” rating in a report on Wednesday, April 24th. StockNews.com downgraded Danaher from a “buy” rating to a “hold” rating in a report on Tuesday, June 25th. Finally, Bank of America raised their target price on Danaher from $258.00 to $270.00 and gave the company a “neutral” rating in a research note on Wednesday, April 24th. Six analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $268.67.

Danaher Stock Performance

Shares of NYSE:DHR traded down $3.63 on Tuesday, hitting $240.88. 1,215,946 shares of the company were exchanged, compared to its average volume of 2,845,540. Danaher has a one year low of $182.09 and a one year high of $269.11. The firm has a market capitalization of $178.42 billion, a price-to-earnings ratio of 40.83, a PEG ratio of 3.82 and a beta of 0.84. The company’s 50 day moving average price is $255.96 and its two-hundred day moving average price is $246.75. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.51 and a current ratio of 1.85.

Danaher (NYSE:DHR) last issued its earnings results on Tuesday, April 23rd. The conglomerate reported $1.92 EPS for the quarter, beating analysts’ consensus estimates of $1.72 by $0.20. The business had revenue of $5.80 billion during the quarter, compared to analyst estimates of $5.62 billion. Danaher had a return on equity of 11.43% and a net margin of 16.78%. Danaher’s revenue was down 2.6% on a year-over-year basis. During the same period in the prior year, the company posted $2.36 earnings per share. Research analysts expect that Danaher will post 7.63 earnings per share for the current year.

Insider Buying and Selling at Danaher

In other news, SVP Brian W. Ellis sold 4,000 shares of the business’s stock in a transaction on Wednesday, April 24th. The shares were sold at an average price of $250.01, for a total value of $1,000,040.00. Following the completion of the transaction, the senior vice president now owns 29,830 shares of the company’s stock, valued at approximately $7,457,798.30. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In related news, SVP Brian W. Ellis sold 4,000 shares of the firm’s stock in a transaction on Wednesday, April 24th. The shares were sold at an average price of $250.01, for a total transaction of $1,000,040.00. Following the sale, the senior vice president now directly owns 29,830 shares in the company, valued at $7,457,798.30. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Alan G. Spoon sold 708 shares of the stock in a transaction dated Thursday, May 2nd. The stock was sold at an average price of $243.58, for a total value of $172,454.64. Following the transaction, the director now owns 116,202 shares of the company’s stock, valued at approximately $28,304,483.16. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 148,783 shares of company stock valued at $37,536,717. Corporate insiders own 10.90% of the company’s stock.

Institutional Trading of Danaher

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Tsfg LLC increased its position in shares of Danaher by 733.3% in the first quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock valued at $25,000 after acquiring an additional 88 shares during the last quarter. Cape Investment Advisory Inc. acquired a new position in shares of Danaher during the 4th quarter worth approximately $25,000. BKM Wealth Management LLC bought a new stake in shares of Danaher during the 4th quarter worth approximately $27,000. Redmont Wealth Advisors LLC bought a new position in shares of Danaher in the first quarter valued at $30,000. Finally, Wetzel Investment Advisors Inc. acquired a new position in Danaher during the fourth quarter worth $29,000. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.